1
Gary G Liversidge, Kenneth C Cundy, John F Bishop, David A Czekai: Surface modified drug nanoparticles. Sterling Drug, Arthur H Rosenstein, William J Davis, September 8, 1992: US05145684 (697 worldwide citation)

Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions conta ...


2
Gary G Liversidge, Elaine Liversidge, Pramod P Sarpotdar: Surface modified anticancer nanoparticles. Eastman Kodak Company, Arthur H Rosenstein, March 21, 1995: US05399363 (279 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


3
Gary G Liversidge, Philip Conzentino Jr, Kenneth C Cundy, Pramod P Sarpotdar: Surface modified NSAID nanoparticles. NanoSystems L L C, Rudman & Balogh, September 3, 1996: US05552160 (175 worldwide citation)

Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit reduced gastric ...


4
Gary G Liversidge, Christopher P Phillips, Kenneth C Cundy: Method to reduce particle size growth during lyophilization. Sterling Winthrop, William J Davis, April 12, 1994: US05302401 (150 worldwide citation)

This invention discloses a composition comprised of nanoparticles having a surface modifier adsorbed on the surface thereof and a cryoprotectant associated therewith, which cryoprotectant is present in an amount sufficient to form a nanoparticle-cryoprotectant composition. A preferred surface modifi ...


5
Gary G Liversidge, David A Engers, Mary E Roberts, Stephen B Ruddy, Sui Ming Wong, Shuqian Xu: Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers. Elan Pharma International, Foley & Lardner, April 4, 2000: US06045829 (110 worldwide citation)

The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a ...


6
Gary G Liversidge, Elaine Liversidge, Pramod P Sarpotdar: Surface modified anticancer nanoparticles. Eastman Kodak Company, Arthur H Rosenstein, February 27, 1996: US05494683 (105 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


7
Gary G Liversidge, Eugene R Cooper, J Michael Shaw, Gregory L McIntire: X-ray contrast compositions useful in medical imaging. Sterling Winthrop, William J Davis, June 7, 1994: US05318767 (97 worldwide citation)

An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmace ...


8
Lawrence de Garavilla, Elaine M Liversidge, Gary G Liversidge: Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions. Nanosystems L L C, Foley & Lardner, November 10, 1998: US05834025 (74 worldwide citation)

Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject wit ...


9
Gary G Liversidge, David A Engers, Mary E Roberts, Stephen B Ruddy, Sui Ming Wong, Shuqian Xu: Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers. Elan Pharma International, Foley & Lardner, May 30, 2000: US06068858 (66 worldwide citation)

The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and ...


10
Gary G Liversidge, W Mark Eickhoff, Kathleen J Illig, Pramod Sarpotdar, Stephen B Ruddy: Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract. Elan Pharma International, Foley & Lardner, August 13, 2002: US06432381 (65 worldwide citation)

Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.